Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Stewart

Showing results (981-990 of 1,171) with videos related to

Pageof 118
Sort By:
The Journal of Pharmacology and Experimental Therapeutics|January 22, 1998
Probenecid alters topotecan systemic and renal disposition by inhibiting renal tubular secretionW C Zamboni, P J Houghton, R K Johnson, et al.
Journal of Pediatric Hematology/Oncology|November 1, 1996
Phase I trial and pharmacokinetic (PK) and pharmacodynamics (PD) study of topotecan using a five-day course in children with refractory solid tumors: a pediatric oncology group studyD G Tubergen, C F Stewart, C B Pratt, et al.
Pediatric Blood & Cancer|January 30, 2015
Comparable efficacy with varying dosages of glucarpidase in pediatric oncology patientsJeffrey R Scott, Yinmei Zhou, Cheng Cheng, et al.
Cancer Research|July 23, 2015
ABCG2 Transporter Expression Impacts Group 3 Medulloblastoma Response to ChemotherapyMarie Morfouace, Satish Cheepala, Sadhana Jackson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 20, 2007
Phase I study of everolimus in pediatric patients with refractory solid tumorsMaryam Fouladi, Fred Laningham, Jianrong Wu, et al.
Biorxiv : the Preprint Server for Biology|May 27, 2024
Select DYRK1A Inhibitors Enhance Both Proliferation and Differentiation in Human Pancreatic Beta CellsPeng Wang, Olivia Wood, Lauryn Choleva, et al.
Advances in Radiation Oncology|January 26, 2026
Natural History and Risk Stratification of Biochemically Recurrent Prostate Cancer Following Definitive Radiation TherapyPaul Riviere, Kylie M Morgan, Tyler Nelson, et al.
Bone Marrow Transplantation|March 20, 2012
A phase I/II study of CY and topotecan in patients with high-risk malignancies undergoing autologous hematopoietic cell transplantation: the St Jude long-term follow-upK A Kasow, C F Stewart, R C Barfield, et al.
The Journal of Biological Chemistry|September 5, 1992
Parathyroid hormone-related protein. Evidence for secretion of a novel mid-region fragment by three different cell typesN E Soifer, K E Dee, K L Insogna, et al.
Journal of Medicinal Chemistry|February 1, 2020
Synthesis and Biological Validation of a Harmine-Based, Central Nervous System (CNS)-Avoidant, Selective, Human β-Cell Regenerative Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase A (DYRK1A) InhibitorKunal Kumar, Peng Wang, Jessica Wilson, et al.
Pageof 118

Showing results (981-990 of 1,171) with videos related to

Sort By:
Pageof 118
The Journal of Pharmacology and Experimental Therapeutics|January 22, 1998
Probenecid alters topotecan systemic and renal disposition by inhibiting renal tubular secretionW C Zamboni, P J Houghton, R K Johnson, et al.
Journal of Pediatric Hematology/Oncology|November 1, 1996
Phase I trial and pharmacokinetic (PK) and pharmacodynamics (PD) study of topotecan using a five-day course in children with refractory solid tumors: a pediatric oncology group studyD G Tubergen, C F Stewart, C B Pratt, et al.
Pediatric Blood & Cancer|January 30, 2015
Comparable efficacy with varying dosages of glucarpidase in pediatric oncology patientsJeffrey R Scott, Yinmei Zhou, Cheng Cheng, et al.
Cancer Research|July 23, 2015
ABCG2 Transporter Expression Impacts Group 3 Medulloblastoma Response to ChemotherapyMarie Morfouace, Satish Cheepala, Sadhana Jackson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 20, 2007
Phase I study of everolimus in pediatric patients with refractory solid tumorsMaryam Fouladi, Fred Laningham, Jianrong Wu, et al.
Biorxiv : the Preprint Server for Biology|May 27, 2024
Select DYRK1A Inhibitors Enhance Both Proliferation and Differentiation in Human Pancreatic Beta CellsPeng Wang, Olivia Wood, Lauryn Choleva, et al.
Advances in Radiation Oncology|January 26, 2026
Natural History and Risk Stratification of Biochemically Recurrent Prostate Cancer Following Definitive Radiation TherapyPaul Riviere, Kylie M Morgan, Tyler Nelson, et al.
Bone Marrow Transplantation|March 20, 2012
A phase I/II study of CY and topotecan in patients with high-risk malignancies undergoing autologous hematopoietic cell transplantation: the St Jude long-term follow-upK A Kasow, C F Stewart, R C Barfield, et al.
The Journal of Biological Chemistry|September 5, 1992
Parathyroid hormone-related protein. Evidence for secretion of a novel mid-region fragment by three different cell typesN E Soifer, K E Dee, K L Insogna, et al.
Journal of Medicinal Chemistry|February 1, 2020
Synthesis and Biological Validation of a Harmine-Based, Central Nervous System (CNS)-Avoidant, Selective, Human β-Cell Regenerative Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase A (DYRK1A) InhibitorKunal Kumar, Peng Wang, Jessica Wilson, et al.
Pageof 118